Zopiclone Increases the Arousal Threshold without Impairing Genioglossus Activity in Obstructive Sleep Apnea.
Sophie G Carter, Michael S Berger, Jayne C Carberry...
https://pubmed.ncbi.nlm.nih.gov/26715227/Actively Recruiting
Led by Flinders University · Updated on 2026-09-02
15
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are studying the effects of combining two sleep-related drugs, eszopiclone and lemborexant, in people who have obstructive sleep apnea OSA with a low arousal threshold and difficulty falling or staying asleep. OSA causes repeated airway narrowing during sleep, leading to disrupted breathing and fragmented sleep. This study focuses on individuals who wake up too easily due to minor airway narrowing, which makes treatment challenging and lowers compliance with standard therapies like CPAP. Participants receive either both eszopiclone 3 mg and lemborexant 10 mg capsules or placebo capsules that look identical. The doses are taken once at bedtime for one night only. The study uses a crossover design, so each participant experiences both the drug combination and placebo on two separate nights up to one month apart. This approach aims to see if targeting two sleep mechanisms together improves sleep and breathing better than previous treatments. Participants undergo two non-consecutive overnight sleep studies to compare sleep quality, breathing measures, and next-day performance between the drug and placebo nights. Researchers will assess changes in OSA severity, oxygen levels, sleep efficiency, arousal index, respiratory control, and muscle responses. Additional tests include balance, sleepiness, driving simulation, and vigilance on the mornings after each sleep study. The study lasts up to about one month between the two sleep assessments.
CONDITIONS
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping
D
Danny J Eckert, PhD
C
Cricket SB Fauska, BA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Flinders University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month between two study nights
Participants take either the combination of eszopiclone and lemborexant or placebo capsules before bedtime on two separate nights. Sleep and breathing are monitored overnight during each night.
2 overnight sleep study visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sophie G Carter, Michael S Berger, Jayne C Carberry...
https://pubmed.ncbi.nlm.nih.gov/26715227/Alexander Sweetman, Leon Lack, R Doug McEvoy...
https://pubmed.ncbi.nlm.nih.gov/32440518/Sophie G Carter, Jayne C Carberry, Garry Cho...
https://pubmed.ncbi.nlm.nih.gov/29976648/Maliheh Ghadiri, Ronald R Grunstein
https://pubmed.ncbi.nlm.nih.gov/32212210/Susheel P Patil, Indu A Ayappa, Sean M Caples...
https://pubmed.ncbi.nlm.nih.gov/30736888/Jocelyn Y Cheng, Daniel Lorch, Alan D Lowe...
https://pubmed.ncbi.nlm.nih.gov/37677076/Danny J Eckert
https://pubmed.ncbi.nlm.nih.gov/28110857/Jocelyn Y Cheng, Gleb Filippov, Margaret Moline...
https://pubmed.ncbi.nlm.nih.gov/32187781/Emma L Gray, David K McKenzie, Danny J Eckert
https://pubmed.ncbi.nlm.nih.gov/27655455/Ume Habiba, Radeyah Waseem, Taha Gul Shaikh...
https://pubmed.ncbi.nlm.nih.gov/36633778/Flinders University
Lead Sponsor